14 research outputs found
Effect of Some Threshing Parameters on Sesame Separation
The threshing section on combine harvester or thresher machine affects grain and stalk separation performance. In this study, effect of some threshing parameters such as drum speed, feed rate and concave open on closed capsules sesame straw sieve in developed threshing unit. Threshing drums used were a rasp bar with tooth type. Three threshing drum speeds of 500, 700 and 900 min-1 (6.5, 9.1, 11.7 m/s) were used to investigations. Three feed rate as 90, 180 and 270 kg/h and three concave open as 20, 35 and 50 mm were used in this study. Four sieves were used for separation of straw. Their mesh numbers are 7, 10, 14 and 18. Results show that the best performance for separation of sesame straw were gave at the maximum drum speeds, minimum feed rates and concave opens experienced in this study
Rapid Germination of a Barley Mutant Is Correlated with a Rapid Turnover of Abscisic Acid Outside the Embryo
Updated sesame genome assembly and fine mapping of plant height and seed coat color QTLs using a new high-density genetic map
Comparison of Statistical Methods Used in the Evaluation of Multiple Genotypes in Sesame
Primary cutaneous B-cell lymphoma: Report of eight cases and review of the literature
PubMed ID: 18613872[No abstract available
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
BACKGROUND: In countries where frontline drug approval is limited to first-generation proteasome inhibitors or immunomodulatory drugs, relapses have been both more frequent and less durable. We investigated real world data on the efficacy and safety of daratumumab monotherapy among patients with relapsed refractory multiple myeloma (RRMM) from Turkey using a prospective early access program. PATIENTS AND METHODS: A total of 42 patients with RRMM after a minimum of 3 previous lines of proteasome inhibitor/immunomodulatory drug-based treatments were included from 25 centers across Turkey. Daratumumab monotherapy was administered intravenously at a dose of 16 mg/kg weekly (cycles 1-2), on alternate weeks (cycles 3-6), and monthly thereafter. RESULTS: The median daratumumab monotherapy duration was 5.5 months (range, 0.2-28.7 months). The overall response rate was 45.2%, including 14 (33.3%) partial responses, 4 (9.5%) very good partial responses, and 1 (2.4%) complete response. The median duration of response was 4.9 months. The median progression-free survival (PFS) was 5.5 (95% confidence interval, 2.6-8.4 months) with 12- and 18-month PFS rates of 35.7% and 31.0%, respectively. The median overall survival was not reached; the 12- and 18-month overall survival rates were 64.3% and 59.5%, respectively. The depth of response had a significant effect on PFS (log-rank test, P = .026). Overall, of the 76 adverse events reported, 33 (43.4%) were grade ≥ 3; only 4 (9.52%) were grade 3 infusion-related reactions. No infusion-related reactions or adverse events led to treatment discontinuation. CONCLUSION: The present findings from our daratumumab early access program have confirmed the efficacy and safety profile of daratumumab monotherapy in heavily pretreated Turkish patients with RRMM
The Turkish experience with therapeutic plasma exchange: A national survey
Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE. © 2019 Elsevier Lt
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
The present study investigated the efficacy and safety profile of
daratumumab monotherapy in 42 patients with relapsed refractory multiple
myeloma through a Turkish early access program. The current findings
have confirmed the efficacy of daratumumab monotherapy in heavily
pretreated patients with refractory multiple myeloma because of the deep
and durable responses and favorable safety and tolerability profile.
Background: In countries where frontline drug approval is limited to
first-generation proteasome inhibitors or immunomodulatory drugs,
relapses have been both more frequent and less durable. We investigated
real world data on the efficacy and safety of daratumumab monotherapy
among patients with relapsed refractory multiple myeloma (RRMM) from
Turkey using a prospective early access program. Patients and Methods: A
total of 42 patients with RRMM after a minimum of 3 previous lines of
proteasome inhibitor/immunomodulatory drug-based treatments were
included from 25 centers across Turkey. Daratumumab monotherapy was
administered intravenously at a dose of 16 mg/kg weekly (cycles 1-2), on
alternate weeks (cycles 3-6), and monthly thereafter. Results: The
median daratumumab monotherapy duration was 5.5 months (range, 0.2-28.7
months). The overall response rate was 45.2\%, including 14 (33.3\%)
partial responses, 4 (9.5\%) very good partial responses, and 1 (2.4\%)
complete response. The median duration of response was 4.9 months. The
median progression-free survival (PFS) was 5.5 (95\% confidence
interval, 2.6-8.4 months) with 12- and 18-month PFS rates of 35.7\% and
31.0\%, respectively. The median overall survival was not reached; the
12- and 18-month overall survival rates were 64.3\% and 59.5\%,
respectively. The depth of response had a significant effect on PFS
(log-rank test, P = .026). Overall, of the 76 adverse events reported,
33 (43.4\%) were grade >= 3; only 4 (9.52\%) were grade 3
infusion-related reactions. No infusion-related reactions or adverse
events led to treatment discontinuation. Conclusion: The present
findings from our daratumumab early access program have confirmed the
efficacy and safety profile of daratumumab monotherapy in heavily
pretreated Turkish patients with RRMM